greeksoup/ stock research

AbbVie (ABBV) FY2014 results: revenue $20.0 billion, up 6.2% on the year

AbbVie Inc. (ABBV) reported revenue of $20.0 billion for fiscal 2014, the year ended 31 December 2014, up 6.2% on the year before. Net income was $1.8 billion, down 57.0%, and diluted earnings per share $1.10. The figures are the company's own, from the 10-K it filed with the SEC on 20 February 2015.

Revenue
$20.0 billion
+6.2% on the year
FY2011FY2014
Operating margin
17.1%
30.1% a year earlier
FY2011FY2014
Net income
$1.8 billion
-57.0% on the year
FY2011FY2014
Diluted EPS
$1.10
-57.0% on the year
FY2011FY2014

this yearthe year beforeHover a bar for its figure.

The year in brief

Income statement (profit and loss)

$ millionFY2014FY2013FY2012On the yearLast 8 years
Revenue19,96018,79018,380+6.2%
Cost of revenue4,4264,5814,508-3.4%
Gross profit15,53414,20913,872+9.3%
Gross margin77.8%75.6%75.5%
Research and development3,2972,8552,778+15.5%
Selling, general and administrative7,7245,3524,989+44.3%
Operating income3,4115,6645,817-39.8%
Operating margin17.1%30.1%31.6%
Interest expense429299104+43.5%
Pre-tax income2,3695,3325,725-55.6%
Income tax5951,204450-50.6%
Effective tax rate25.1%22.6%7.9%
Net income1,7744,1285,275-57.0%
Net margin8.9%22.0%28.7%
Diluted EPS$1.10$2.56$3.35-57.0%
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionFY2014FY2013FY2012On the yearLast 8 years
Operating cash flow3,5496,2676,345-43.4%
Capital expenditure612491333+24.6%
Free cash flow2,9375,7766,012-49.2%
Free cash flow margin14.7%30.7%32.7%
Depreciation and amortisation7868971,150-12.4%
Share-based compensation241212187+13.7%
Buybacks665320n/a+107.8%
Dividends paid2,6612,555n/a+4.1%
Dividend per share$1.75$2.00n/a-12.5%
Diluted shares, weighted1,610m1,604m1,577m+0.4%

Balance sheet

$ millionFY2014FY2013FY2012On the yearLast 8 years
Shareholders' equity1,7424,492-350-61.2%
Debt14,97714,72315,672+1.7%
Other liabilities10,8289,98311,686+8.5%
Total liabilities and equity27,54729,19827,008-5.7%
Fixed assets2,4852,2982,247+8.1%
Goodwill5,8626,2776,130-6.6%
Intangible assets1,5131,8902,323-19.9%
Investments1184182,194-71.8%
Cash and equivalents8,3489,5955,901-13.0%
Inventory1,1241,1501,091-2.3%
Other assets8,0977,5707,122+7.0%
Total assets27,54729,19827,008-5.7%

10-K for the year ended 31 December 2014, filed 20 February 2015: the filing.